Source-grounded facts extracted from Vera Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Vera Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-21 meeting.
“Proposal 3 – Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows: For Against Abstain Broker Non-Votes 56,585,568 2,433,537 84,276 2,863,469”
Vera Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The final voting results are as follows: For Against Abstain 61,834,842 44,710 87,298”
Vera Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.
“Proposal 1– Election of Directors. The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Michael M. Morrisey, Ph.D. 45,288,710 13,814,671 2,863,469 Patrick G. Enright 54,697,296 4,406,085 2,863,469 James R. Meyers 58,946,269 157,112 2,863,469”
Vera Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income a net loss of $121.0 million, EPS a net loss per diluted share of $1.69.
“For the quarter ended March 31, 2026, Vera Therapeutics reported a net loss of $121.0 million, or a net loss per diluted share of $1.69”
Vera Therapeutics, Inc. incurred credit facility of up to $500.0 million with Oxford Finance LLC at greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70% maturing June 1, 2030, or June 1, 2031.
“On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million.”
David Johnson was appointed as Chief Operating Officer at Vera Therapeutics, Inc..
“On July 1, 2024, Vera Therapeutics, Inc. (the “ Company ”) announced the appointment of David Johnson as the Company’s Chief Operating Officer, effective July 1, 2024”
Christy Oliger was appointed as Director at Vera Therapeutics, Inc..
“On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.”
Vera Therapeutics, Inc. shareholders approved Ratification of the Selection of KPMG LLP as the independent registered public accounting firm at the 2024-05-15 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Vera Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal.”
Vera Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $28.4 million, or a net loss per diluted share of $0.56, EPS net loss per diluted share of $0.56.
“For the quarter ended March 31, 2024, the company reported a net loss of $28.4 million, or a net loss per diluted share of $0.56, compared to a net loss of $30.1 million, or a net loss per diluted share of $0.80, for the same period last year.”
Vera Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income a net loss of $96.0 million, or a net loss per diluted share of $2.25, EPS net loss per diluted share of $2.25.
“For the year ended December 31, 2023, the company reported a net loss of $96.0 million, or a net loss per diluted share of $2.25”
Robert M. Brenner was appointed as Chief Medical Officer at Vera Therapeutics, Inc..
“The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.”
Celia Lin departed as Chief Medical Officer at Vera Therapeutics, Inc..
“On January 8, 2024, Vera Therapeutics, Inc. (the "Company") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the "Separation Date").”
Vera Therapeutics, Inc. incurred term loan of $25.0 million with Oxford Finance LLC at the greater of (i) 8.25% and (ii) the sum of (a) 1-Month CME Term SOFR and (b) 8 maturing December 17, 2027.
“On December 22, 2023, Vera Therapeutics, Inc. (the “Company”) drew down an aggregate of $25.0 million in new term loans pursuant to its previously disclosed Loan and Security Agreement, dated December 17, 2021, as amended (the “Loan Agreement”), by and between the Company and Oxford Finance LLC (the “Lender”).”
Vera Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.1 million, EPS $0.45.
“For the quarter ended September 30, 2023, the company reported a net loss of $20.1 million, or a net loss per diluted share of $0.45”
Vera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $20.2 million, or $0.46 per share, EPS $0.46 per share.
“For the quarter ended June 30, 2023, the company reported a net loss of $20.2 million, or $0.46 per share, compared to a net loss of $14.9 million, or $0.55 per share, for the same period last year.”
Vera Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm at the 2023-05-10 meeting.
“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 35,575,486 3,251 12,777 —”
Vera Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-05-10 meeting.
“The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Maha Katabi, Ph.D. 27,427,581 1,803,342 6,360,591 Michael M Morrissey, Ph.D. 25,666,331 3,564,592 6,360,591 Patrick G. Enright 29,205,775 25,148 6,360,591”
Vera Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income net loss of $30.1 million, EPS net loss per diluted share of $0.80.
“For the quarter ended March 31, 2023, the company reported a net loss of $30.1 million, or a net loss per diluted share of $0.80”
Vera Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income net loss of $89.1 million, EPS a net loss per diluted share of $3.35.
“For the year ended December 31, 2022, the company reported a net loss of $89.1 million, or a net loss per diluted share of $3.35”
Vera Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income a net loss of $24.7 million, or a net loss per diluted share of $0.91, EPS $0.91.
“For the three months ended September 30, 2022, the company reported a net loss of $24.7 million, or a net loss per diluted share of $0.91, compared to a net loss of $7.6 million, or a net loss per diluted share of $0.36, for the same period last year.”
Michael M. Morrissey, Ph.D. was appointed as Chair of the Board and Director at Vera Therapeutics, Inc..
“the Board appointed Michael M. Morrissey, Ph.D., to the Board, to fill the vacancy resulting from Mr. von Emster’s resignation, and to serve as Chair of the Board, effective on the Annual Meeting Date.”
Kurt von Emster resigned as Director and Chair at Vera Therapeutics, Inc..
“Kurt von Emster notified the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) of his resignation as a director of the Company and as Chair of the Board, effective on the date of the Company’s 2022 Annual Meeting of Stockholders.”
Kimball Hall was appointed as Director at Vera Therapeutics, Inc..
“On December 10, 2021, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Kimball Hall to the Board, effective immediately.”
Sean P. Grant was appointed as Chief Financial Officer at Vera Therapeutics, Inc..
“On July 14, 2021, Vera Therapeutics, Inc. (the “Company”) announced the appointment of Sean P. Grant as the Company’s Chief Financial Officer, effective July 12, 2021 (the “Start Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.